Amine salts of an integrin receptor antagonist

The present invention relates to particular salts of an integrin receptor antagonist. More particularly, the invention relates to amine salts of 3-(2-methyl-pyrimidin-5-yl)-9-(5,6,7,8-tetrahydro-[1,8]-naphthyridin-2-yl)-nonanoic acid, which are potent integrin receptor antagonists. These novel salts are therefore useful for the treatment and prevention of diseases and conditions for which an antagonist of the integrin receptor is indicated. Amine salts of -(-methyl-pyrimidin--yl)--(-tetrahydro-[]-naphthyridin--yl)-nonanoic acid are potent antagonists of the integrin v receptor and are useful for the prevention and/or treatment of osteoporosis and vascular restenosis, as well as conditions associated with excessive angiogenesis, such as macular degeneration, diabetic retinopathy, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth. The invention also relates to a process for the preparation of the novel salts as well as pharmaceutical compositions containing the salts and methods of using the salts. Also disclosed are (R)- and (S)-(-methylpyrimidin--yl)--(-tetrahydro-[]naphthyridin--yl)-nonanoic acid in the form of a zwitterion trihydrate.